CureMatch, Inc.

??Such a delight to be back in Boston for the TargetCancer Foundation “Think Tank on advancing #PrecisionMedicine in #RareCancers, 2024”. Always a pleasure to start the morning with Razelle Kurzrock & Wafik S. El-Deiry, MD, PhD, FACP OncoAlert Looking forward to delivering a talk “Revolutionizing Rare Cancer Drug Development with Novel Tumour-Agnostic Classifiers and AI Innovations” #AI #PrecisionOncology #RareCancer

We are #pancancer and only require the #NGS lab work pdf to then produce our CureMatch report. See more at: www.curematchdirect.com

CureMatch Value Narrow Down Therapy Options: ? #Therapy options based on all the detected markers and all available drugs considered integratively, not just independently one at a time ? Reconcile cases with too many targets but only few drugs can be attempted at once ? Reduce from lists of many therapies on #NGS reports additional guidelines to only those that have molecular rationale and are on the formulary guidelines, on-label Score any options physicians are thinking of (optional) Help do no harm and avoid "triple-toxicity" (clinical, psychological, financial) by alerting to #drugresistance and possibly harmful therapies Exclude any drugs based on prior history Additional Unique Options: Any complex cases when physicians need #MolecularTumorBoard level advice but NO options on-label: ? All standard-of-care therapies failed ? Occult Primary, so no clear standard of care ? #Rarecancer, nothing is approved for it yet ? Unique Pediatric cases Match to Trials: ? #clinicaltrial options focused on molecularly-matching therapies

#Earlydetection is critical, getting a second opinion before starting a treatment is highly recommended, and ask for #NGS lab work to determine the molecular makeup of the #cancer. No two are ever the same, even if found in same organ. That lab PDF output, is our @curematch input to cater to each specific patient’s cancer. #artificialintelligence #precisionmedicine #oncology www.curematchdirect.com

In a new paper published in Nature Magazine, researchers at Memorial Sloan Kettering Cancer Center (MSK) are demonstrating that cancer outcome predictions can be improved by breaking down hospitals’ traditional data silos with the help of artificial intelligence (#AI). Learn more: https://lnkd.in/gCXK828y

Investigators tracked clinical and treatment outcomes for advanced cancer patients who had tumor testing with an in-house assay developed by Providence Health.

I'm excited to be at this year’s HLTH Inc. USA conference, #HLTH24, surrounded by so many inspiring innovators all committed to one purpose: transforming #healthcare to deliver better care for patients around the world. I'm looking forward to hearing from so many industry leaders – including our very own Joaquin Duato and Vanessa Broadhurst – on the big, bold ideas that will shape define the future of healthcare. I’m also personally excited to be speaking on Monday afternoon from 2:20-3:00 pm on the Bold Stage re: how we’re harnessing #bigdata and cutting-edge technologies to enable more personalized care for patients. As the conference kicks off, Johnson & Johnson is sharing 6 ways we’re leveraging the power of #artificialintelligence across our company – from Johnson & Johnson Innovative Medicine to Johnson & Johnson MedTech | Surgery – to advance #innovation and improve outcomes for patients, including by: ? ??Speeding up the process of discovering new medicines? ??Enabling more targeted clinical trial recruitment? ??Enabling more personalized care? ??Helping treatments reach patients faster? ?Analyzing the operating room for efficiency and physician learning? ??Improving surgical procedures? ? I’m incredibly proud of the work we’re doing across #MyCompany to unite the best of #science and #technology to deliver for patients. If you’ll be in Las Vegas and are interested in connecting to learn more, please don’t hesitate to be in touch. Hope to see many of you this week at #HLTH2024! https://lnkd.in/eSJkXH-5?

CureMatch can help accelerate #Cancer focused #clinicaltrials. A significant amount of time for clinical trials is spent recruiting patients, and many trials do not recruit the required number of people. Our KRR (Knowledge, Representation & Reasoning) AI can help in designing trial criteria & identifying suitable patients for trials based on their #NGS lab work from any lab.

Excited to be part of CureMatch, Inc.'s mission to improve cancer care and accelerate drug discoveries in Precision Medicine.?? CureMatch's proprietary technology and algorithms are transforming the process of how to best match and rank the optimal combination of novel drugs and treatments for patients and population based on their molecular tumor profile. ? The platform is empowering patients and providers with the knowledge to make informed and cost-effective treatment decisions.?? #precisionmedicine #oncology #personalizedmedicine #genomics #cancer #clinicaltrials #lifesciences #AI #RWD #precisiononcology

I’m excited to share positive topline overall survival results from our Phase 3 study in men with metastatic castration-resistant #prostatecancer (mCRPC).?Read our press release here: ?https://lnkd.in/gzWRPSbC ?? mCRPC is the most advanced and aggressive stage of prostate cancer, and patients are in high unmet need for additional effective treatment options. These positive results highlight the long-standing commitment of our team at [TAG] Pfizer to improving outcomes for people living with prostate cancer.?